One of the largest studies of patients taking GLP-1 drugs like Ozempic, Wegovy, Maunjaro etc for diabetes and obesity was conducted and it revealed tremendous benefits of these drugs beyond metabolic disease and weight management. Unfortunately, it also revealed some risks of taking these drugs that were unexpected.
The researchers studies the health outcomes of over 200,000 patients on these GLP-1 drugs and compared to a control group of nearly 1.7 million patients on other types of diabetes medications. Beyond diabetes and weight loss, the study revealed, benefits for lowering cardiovascular and kidney diseases. It further found a reduced risk of Alzheimers (12%), psychotic disorders (18%) and addiction disorders (13%). These results demonstrate that the benefits of GLP-1 drugs go far beyond it’s original intended use.
The lead investigator on this study speculated that since GLP-1 drugs act on the brain center for reward and craving, these drugs may find use in treating certain addiction disorders.
The news is not all positive though. The study also found that the risk of certain diseases like arthritis and pancreatitis increases.
While no drug is completely free of potentially adverse side effects, overall, GLP-1 drugs are already demonstrating massive benefits to human metabolic health and now the benefits appear to extend well beyond just diabetes and weight control.
Reference:
Comments are closed